Ordesekimab  (Synonyms: AMG 714; PRV-015)

Ordesekimab (AMG 714; PRV-015) is a fully human IgG1κ anti-IL-15 (Interleukin Related) monoclonal antibody. The binding of Ordesekimab to IL-15 inhibits the interaction of IL-15 with the IL-2Rβ and common γ chain of the IL-15 receptor complex, but not with the IL-15Rα chain. Ordesekimab has the potential for study of nonresponsive celiac disease (NRCD)^[1].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

The simultaneous binding of Ordesekimab (AMG 714) to the Fcγ receptor (R) IIIα expressed on natural killer (NK) cells and to the IL-15/IL-15Rα complex on cells such as monocytes may theoretically enable antibody-dependent cell-mediated cytotoxicity (ADCC) toward the IL-15Rα-expressing cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

3600  [NCBI]

P40933

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

145.12 kDa

879293-15-9

Liquid

Colorless to light yellow

[Ordesekimab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Immobilized Human IL-15, His Tag can bind Ordesekimab. The EC₅₀ for this effect is 62 ng/mL.
• 
  Flow Cytometry analysis of Hela cells labelling IL-15 (red) with Ordesekimab (anti-IL-15) (HY-P99410). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.

• [1]. Yu-Ling Wei, et al. Strategies to evaluate potential effector function of glycan variants: a case study of ordesekimab (AMG 714 or PRV-015). J Immunotoxicol. 2022 Dec;19(1):109-116.  [Content Brief]